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health-insured patients: from the 4th day of disability, the Instituto Mexicano del 
Seguro Social covers 60% of wages, 2) Private health-insured: economical loss of 
private beneficiaries is a 20% co-pay plus daily average income lost. 3) No-health-
insurance: Medical costs and absenteeism represent the economical loss. Costs are 
expressed in 2014 USD (1USD= 13MXN). Morbidity cases were extracted from pub-
lished data by National Institute of Public Health and used to calculate a weighted 
average of economical losses for each scenario. Results: The distribution of 
people with smoking-related disease (AMI, COPD and LC) was 25.0%, 65.4% and 
9.6%, respectively. Patients in scenario 1) 2) and 3) spend/lose an average of $446.6, 
$8,448.2 and $37,384.95 per year, respectively (medical costs are the drivers of the 
economic resources lost by not-insured population). Average illness expense derived 
from tobacco consumption regarding the proportion of people in each scenario 
was $13,917 yearly (local per capita GDP is $9,749). Regardless of health-insurance 
status, LC is the most expensive disease ($39,564.26), followed by AMI and COPD 
($14,337.06 and $10,109.32, respectively). ConClusions: The study showed that in 
the long run smokers incur significant economic losses even if they have medical 
insurance. Costs increases to people that do not have any insurance.
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objeCtives: To assess and compare the costs of first-line monoclonal antibodies 
(mABs) treatment protocols in breast cancer, non-Hodgkin lymphoma and colo-
rectal carcinoma in South-Εastern Europe. Methods: A retrospective, bottom-up 
case series study design was implemented with one-year time horizon and payer’s 
perspective. The study sample size was 265 patients (breast cancer, N= 137, colorec-
tal cancer, N= 44, and non-Hodgkin lymphoma, N= 84) while treatment protocols 
included adjuvant mAbs: trastuzumab (N= 137), bevacizumab (N= 28), cetuximab 
(N= 16) and rituximab (N= 84). ICD-10 related, direct medical and lost productivity 
costs (€ ) across treatment groups during 2010-2013. Results: The average length 
of observation was 128±97 days per patient. Total mean direct and indirect costs 
of care were: trastuzumab breast cancer group € 17,740; bevacizumab colorectal 
carcinoma group € 8,775; cetuximab colorectal carcinoma group € 27,181 and rituxi-
mab non-Hodgkin lymphoma group € 19,431. An average mAbs-treated patient 
incurred € 17,897 costs of medical care. The total combined budget of these 265 
patients was € 4,742,775. ConClusions: The use of mAbs strongly correlated with 
high costs in first-line cancer medical care and dominated other cost domains. 
Cetuximab-based treatment protocol in colorectal carcinoma patients was sub-
stantially more expensive compared to trastuzumab (C50); bevacizumab (C20) 
and rituximab (C80) alternatives. Extremely high costs of mAbs are the key-issue 
for Eastern European policy makers by crossing the upper limits of affordability 
in middle-income economies.
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objeCtives: Isolated limb perfusion and infusion (ILP/ILI) are therapies for region-
ally metastatic melanoma where high doses of anticancer drugs are delivered 
directly into the circulation of an affected limb, while minimizing systemic drug 
exposure. This procedure can lead to high response rates but without proven ben-
efits to overall survival. It is recommended by ESMO and NCCN guidelines as a treat-
ment option for patients with stage III unresectable metastatic melanoma. However, 
limited information is available on its use pattern and costs in the literature. This 
study was to examine patterns of ILP/ILI use and associated costs in patients with 
melanoma in the US. Methods: This is a retrospective, observational study using 
large administrative claims from the MarketScan® databases. Patients who under-
went ILP/ILI (CPT-4: 36823) with diagnosis of melanoma (ICD-9-CM: 172. xx, V10.82) 
between 1/1/2002 and 3/31/2013 were included. Patient characteristics, use patterns, 
hospital length of stay, and costs (2013 US $) of ILP/ILI were assessed. Results: 
A total of 113 patients met the study criteria and were included in the analysis. The 
mean age was 62.1 years (standard deviation [SD] 14.1); 39.8% were male. The mean 
baseline Charlson’s comorbidity index was 0.24 and 36.4% of patients were Medicare 
beneficiaries. Overall, 86.4% of patients had melanoma in the lower limb, 12.7% in 
the upper limb, and 0.9% in both upper and lower limbs; 59.3% had lymph node 
metastasis and 56.8% had skin metastasis. Four patients (3.5%) underwent multiple 
ILP/ILI procedures. The mean (±SD) hospital length of stay was 5.6 (± 3.5) days and 
the mean (±SD) cost was $35,898 (± $26,492) per ILP/ILI procedure. ConClusions: 
The use of isolated limb perfusion and infusion was associated with relatively long 
hospital stay and high cost. The results of this study may provide source data for 
economic evaluations of treatment options for regionally metastatic melanoma.
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objeCtives: To estimate the resource use and costs a health plan can anticipate 
during the diagnosis, treatment, and surveillance of a patient with metastatic unre-
for France and Germany in year 1 and 2, were € 502 - € 126 for France; € 1,429 - € 1,156 
for Germany. Total costs reached € 18,024 (yr1), € 7,039 (yr2) France; € 19,025 (yr1), 
€ 13,295 (yr2) Germany; € 15,785 (yr1), € 1,990 (yr2) England. Two-year costs totalled 
€ 25,063 (France); € 32,500 (Germany); € 17,777 (England). Subgroup analyses showed 
higher costs for elderly patients, those with non-metastatic disease and smokers.  
ConClusions: Considerable differences in average treatment costs were observed. 
In-patient costs dominate in the first year of treatment in all countries. The study 
highlights the costly nature of NSCLC.
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objeCtives: Best supportive care (BSC) is in general individually provided to 
patients. Thus, the scope of BSC and its costs can vary widely. Only limited 
information on BSC costs for patients with non-small cell lung cancer (NSCLC) 
exists. Aim of this research was to estimate annual BSC costs for NSCLC patients 
in Germany. Methods: To estimate BSC costs at first a literature search in 
PubMed with the key words “best supportive care”, “cost”, “non-small cell lung 
cancer” and “economic analysis” individual and combined search terms was 
performed. International publications of economic evaluations including data 
on single cost items which could be applied to the German health care system 
were included. Additionally, data on BSC from a NSCLC patient registry (n= 193) 
and prescription data derived from a randomised controlled trial (RCT) were used 
as further references. Cost- items were extracted from each reference and finally 
applied to the German inpatient and outpatient reimbursement system. Results: 
The literature research yielded 317 records of which 3 met the inclusion crite-
ria (2= UK; 1= North America). An extrapolation of these evaluation results to the 
German health care system showed that BSC costs based on UK data ranged 
from 16,940€ to 45,426€ (North America: 31,352€ ). According to health economic 
data from an RCT annual cost for BSC amounted to 17,531€ , while data from a 
NSCLC patient registry added up to 28,070€ . The average annual costs for BSC 
were estimated at 27,864€ . ConClusions: Since BSC is individually delivered 
to patients, it leads to a high variance of annual BSC costs for NSCLC patients in 
Germany. Furthermore, international economic evaluations were extrapolated 
to the German health care system. Hence, results should be interpreted with 
caution as international treatment guidelines and reimbursement schemes are 
not fully applicable to Germany. Future analyses should be based on a German 
population only.
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objeCtives: Treatment for breast cancer is usually based on chemotherapy 
and radiotherapy, but in unsuccessful cases, mastectomy is required. In Brazil, 
mastectomies are performed as simple or radical, with lymphadenectomy. This 
study aims to relate geographic distribution, temporal trends and economic profile 
of this procedure in Brazil. Methods: Assessments about hospital admissions 
were performed to analyze costs and geographic distribution among mastectomies 
related with breast cancer realized in Brazil, from January 2008 to December 2012. 
The data used were extracted by Brazilian Hospital Information System (SIH/SUS) 
database, according to ICD-0416120032 (simple mastectomy) and ICD-0416120024 
(radical with lymphadenectomy). Costs were estimated in 2014 Brazilian Real (BRL) 
and represents federal reimbursement values for hospitalizations (exams, drugs, 
medical procedures and fees). Results: In Brazil, the number of mastectomies 
related with breast cancer ranged from 8,687 in 2008 to 9,703 in 2012. In Southeast 
region were performed 22,977 procedures, which was the largest number per 
region, compared with 1,814 in North; 8,443 in South; 2,280 in Midwest and 10,538 
in Northwest. In São Paulo; 10,111 procedures occurred in this period, while 8 were 
performed in Amapá. Total costs with mastectomies due to breast cancer in Brazil 
during this period were 44,219,235.66 BRL. The value per patient increased about 
12,5% over the years with mean costs from 2008 to 2012 of 799.75BRL, 842.62BRL, 
845.28BRL, 878.20BRL and 870.25BRL, respectively. In 2010, the mean mortality rate 
among simple and radical mastectomies was 0,22% and increased until 0,54% in 
2012. ConClusions: Geographic distribution of mastectomy due to breast cancer 
in Brazil is concentrated in Southeast region, in comparison to other regions and 
from 2008 to 2012 there was no change in this pattern. Although costs elevated, 
mortality also increased in this period.
PCN88
estimatioN oF eCoNomiC Losses resULtiNg From diseases assoCiated 
with smokiNg iN mexiCaN iNsUred aNd UNiNsUred PoPULatioN
Muciño-Ortega E.1, Hernandez-Reyes F.C.1, Reynales-Shigematsu L.2
1Pfizer S.A. de C.V., Ciudad de México, Mexico, 2Instituto Nacional de Salud Pública, Cuernavaca, 
Mexico
objeCtives: Few data has been published in Mexico related to direct smoking 
costs from the consumer perspective. To estimate lost income and pocket costs 
related to smoking diseases from the perspective of Mexican families. Methods: 
The analysis incorporated patients with public, private and no-health insurance 
from 18-65 years. Through Mexican literature review, medical costs and prevalence 
of 3 major diseases associated with tobacco consumption were identified: acute 
myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD) and lung 
cancer (LC) as well as absenteeism associated to each disease. Average income was 
extracted from 2012 national income survey. Scenarios evaluated were: 1) Publicly 
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areas. disClosuRe: The EHR4CR project is mandated by the Innovative Medicines 
Initiative (co-funded by the European Commission and EFPIA).
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objeCtives: The aim was to determine the cost-effectiveness of colonic stent inser-
tion for the management of malignant bowel obstructions. Colonic stents are a 
minimally invasive alternative to open surgery for patients medically unfit for single 
stage surgery. Methods: Two economic models were developed. The first compared 
patients who received palliative or definitive stents and were not medically fit for 
re-anastomosis. The second compared patients who received stents as a bridge-to-
surgery and were medically fit for a second stage of two-stage surgery, this included 
colostomy or Hartmann’s procedure. ResultsFor patients requiring palliation, the 
cost of colonic stent insertion was estimated to be $17,809 compared to $20,516 for 
palliative colostomy (a saving of $2,707). The benefits associated with both proce-
dures were 0.099 QALYs and 0.089 QALYs gained, respectively, an incremental benefit 
of 0.01 QALYs per patient. For patients requiring a bridge-to-surgery, the cost of 
colonic stent insertion was estimated to be $29,729, compared to $30,169 for patients 
that received multi-stage surgery (either a colostomy or a Hartmann’s procedure). 
This represented a cost savings of $440. The estimated average patient would gain 
0.510 QALYs compared to 0.458 QALYs in the multi-stage surgery group. This yields 
an incremental benefit of 0.052 QALYs per patient. The main drivers of both models 
were the technical and clinical success of the stent insertion, and length of hospital 
stay following the procedures. The probability of a resection with primary anas-
tomosis after insertion of a stent and the cost of stenting were also drivers in the 
bridge-to-surgery model. ConClusions: In terms of cost-effectiveness, colonic 
stent insertion for malignant bowel obstruction in patients requiring palliation or 
a bridge-to-surgery dominated the current alternative surgical procedures.
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objeCtives: The aim of this study is to develop and validate a decision-analytic 
model describing the current course of disease, including treatment, in metastatic 
colorectal cancer. This baseline model will serve as the comparator in analyses of the 
(cost-) effectiveness of new treatment strategies. Methods: An individual-based 
micro-simulation model was constructed based on the disease states a patient 
may experience after a diagnosis of metastatic colorectal cancer. The states include 
first-line second-line and third-line treatment, as well as states of progression of 
disease after first-, second- or third-line, finally a death state is included. Time spent 
in each disease state was predicted using log-logistic, log-normal or weibull survival 
models, each dependent on a number of patient characteristics. All survival models 
and patient characteristics were based on patient-level data, provided by the CAIRO 
trial (NCT00312000). Two oncologists evaluated the model for face validity, the model 
was further validated by comparing various model outcomes with the original data, 
the national cancer registry and a population based study. Results: There were no 
significant differences in patient and treatment characteristics, nor intermediate 
and overall survival estimates between the simulated and original patient-level 
data. External validation with national cancer registry data showed few differences 
in survival with the simulated data. Additionally the simulated survival did not 
significantly differ from the survival as recorded in a pilot oxaliplatin study of 119 
patients who were observed in the same timeframe as the RCT. ConClusions: The 
micro-simulation decision model described in this article underwent an internal 
and external validation and can be used to evaluate new possibilities for research 
and treatment in metastatic colorectal cancer.
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objeCtives: The evaluation of the economic consequences of 21-gene RT-PCR assay 
OncotypeDX introduction to the reimbursement scheme of National Organization 
for Health Provision-EOPYY. Methods: A decision tree was developed concerning 
two treatment scenarios for the year 2013: a) chemotherapy admission according the 
common treatment practice without the application of the test vs b) chemotherapy 
admission depending on the results of the test. The sub-group of breast cancer 
patients appropriate for applying the test was determined according international 
guidelines and included early stage breast cancer women with hormone receptor 
positive and lumph node negative age ≤ 65 years. Cancer incidence was derived from 
ELSTAT and OECD base, while some assumptions were made concerning the age 
structure and disease stage of the population. The percentages of women assessed 
as high risk (score> 31) for recurrence were obtained from EOPYY data for 2013. The 
estimated cost for OncotypeDX test was set according the EOPYY reimbursement 
price (€ 2,848 for 2013). Cost of chemotherapy and other cost items (eg laboratory 
sectable osteosarcoma using national guideline recommendations. Methods: 
An economic disease model was developed based on recommendations from the 
2013 NCCN Clinical Practice Guidelines in Oncology for bone cancer. The model 
quantified resource use for diagnosis, 12 months of treatment, and 12 months 
of surveillance of a metastatic unresectable osteosarcoma patient. Costs in 2014 
dollar value were derived from publically available sources for reimbursement of 
CPT codes, HCPCS codes, and generic WAC prices for medications. Chemotherapy 
dosing was based on NCCN recommended treatment regimens. Results: The 
diagnostic cost was estimated to be $1,706 per patient. Treatment costs, consist-
ing of stereotactic radiosurgery and chemotherapy with drug monitoring, varied 
widely across the four NCCN recommended regimens due to differences in the 
price of pharmacotherapy. The chemotherapy regimens were estimated to be the 
major cost components associated with this disease. Doxorubicin, cisplatin, and 
high-dose methotrexate cost $103,051 per patient; doxorubicin and cisplatin cost 
$17,549 per patient; doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide 
cost $38,404 per patient; and cisplatin, ifosfamide, and epirubicin cost $38,936 per 
patient. Additionally, stereotactic radiosurgery was estimated at $2,755 per patient, 
and the cost of drug monitoring during the one year of chemotherapy averaged to 
$5,899 per patient. Additionally, one year of disease surveillance cost $4,264 per 
patient. ConClusions: A guideline-based disease model can assist health plans 
to better understand and anticipate the expected diagnosis, treatment, and sur-
veillance resources and costs for unresectable metastatic osteosarcoma patients.
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objeCtives: The objective of this cost study was to measure the resource utilisa-
tion and the direct costs associated with health care management of metastatic 
malignant melanoma (mMM) in Slovakia and provide a basis for cost-effectiveness 
evaluations. Methods: The cross-sectional survey was performed and included 3 
oncologists experienced in mMM management. The survey was performed to obtain 
the information on the management of patients with mMM and to estimate the 
direct costs of the disease. The studied population were 3 cohorts of mMM patients 
which are usually identified as the health states in the cost-effectiveness models: 
“Before progression“, “Disease progression“ and “Terminal care“. Costs of drugs 
were assesed separately from health states and rated particularly according to BRAF 
positivity. The cost data were assessed for the year 2013. All types of health care used 
in mMM management were evaluated (outpatient and inpatient visits, diagnostics, 
prescription drugs and medical examinations). Costs of adverse events (AEs) were 
set for one single event. Results: The most frequent treatment regimens used in 
the first treatment line of BRAF mutant and BRAF negative patients were identical 
- dacarbazin (94.9% of treated patients), fotemustin (4.5%) and ipilimumab (0.6%). 
Monthly costs of mMM management in addition to the active treatment in the 
state “Before progression“ count for 6.64% (€ 188.51/patient), during the “Disease 
progression“ it was 45.56% (€ 1 294.31/patient) and during the “Terminal state of 
patient“ 47.80% (€ 1 358.02/patient). Adverse event (AE) costs were evaluated for 
grade 3 and 4. The most costly AEs were neutropenia (€ 1 014.66), fever (€ 364.87) and 
rash (€ 230.35). ConClusions: In the management of mMM (excluding the active 
drug cost), the most expensive are the costs of hospitalization and symptomatic 
treatment. The most costly period is the “Terminal state“.
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objeCtives: The EHR4CR 4-year research partnership between the European Union 
and the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
has developed a platform for the trustworthy reuse of hospital electronic health 
records’ data for clinical research. A cost-benefit assessment (CBA) was conducted 
from the pharmaceutical industry perspective to assess the value of the first two 
EHR4CR clinical research scenarios (S): Protocol feasibility assessment (S1), and 
Patient identification and recruitment (S2), either used individually or sequentially 
within a clinical trial workflow, versus current practices. Methods: The EFPIA 
partners have conducted a resource utilization assessment to calculate the actual 
person-time and cost of performing S1 and S2 for one oncology clinical study (Phase 
II or Phase III) as reference case. Assuming that an estimated 50% reduction in actual 
person-time and cost under EHR4CR conditions would directly translate in acceler-
ated time to market (TTM), potential benefits to global pharmaceutical industry were 
derived using global market values (2012) of oncology products1. Absolute cost-ben-
efit analyses were conducted using Monte-Carlo simulations. Results: Compared 
to current practices, individual EHR4CR scenarios S1 and S2 have yielded efficiency 
gains of 134 days and 37 days respectively, and of 171 days when used sequentially. 
Should these efficiency gains from study design optimisation translate in faster 
TTM, corresponding estimated benefits for the global pharmaceutical oncology 
franchise could reach 160,45, and 205 Million € , respectively. ConClusions: This 
CBA is the first to assess the value of EHR4CR scenarios for oncology clinical trials. 
The results confirm that the EHR4CR platform could generate substantial added 
value for pharmaceutical industry should its efficiency gains translate in faster 
TTM. Further benefits are expected from the EHR4CR platform in other therapeutic 
